RIGL
Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03
Figures on this page computed 2026-11-08 12:40 UTC
Last close
51.29USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-03
1.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-03
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth22.1%89 of 100, above its sector
- Returns on capital93.8%99 of 100, above its sector
- Margins93.3%97 of 100, above its sector
- Price1.9x62 of 100, above its sector
- Safety2.4266 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
What it sells, to whom
lens 8 of 9What it sells
1Each band is a share of itself. A segment and a place are two cuts of the same revenue, so they are never added together.
1 segments, 0 places and 0 named customers, each as the filer published it.
1 segments, 0 places and 0 named customers, each as the filer published it.
Every figure in this lens
Single reportable segment294,282,00010-K for 2025, filed 2026-03-03
- Source
- filed
- Statement
- segments
- Fiscal year
- 2025
- Accession
- 0001034842-26-000015
- Reported in
- USD